Ipsen outlays $1bn for China-based Simcere's preclinical ADC [Yahoo! Finance]
Sutro Biopharma, Inc. (STRO)
Last sutro biopharma, inc. earnings: 11/8 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
The French drugmaker has signed a licensing deal with Simcere Zaiming for SIM0613, an ADC asset due to start clinical development in 2026. The agreement sees Ipsen secure global rights for the cancer treatment outside of Greater China, with Simcere Zaiming eligible for upfront, development, regulatory and commercial milestone payments that could reach $1.06bn. Ipsen will have manufacturing rights, along with taking charge of Phase I preparation activities and submission of regulatory applications. The therapy has demonstrated “robust tumour regressions in multiple in vivo preclinical models”, according to Ipsen. The pharma company is eyeing the launch of a Phase I trial evaluating SIM0613 in cancer patients in the second half of 2026. SIM0613 targets the leucine-rich repeat-containing 15 (LRRC15), a protein highly expressed on various tumour types and cancer-associated fibroblasts but with limited expression on normal cells. Like other ADCs, the drug works in a targeted approach,
Show less
Read more
Impact Snapshot
Event Time:
STRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STRO alerts
High impacting Sutro Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
STRO
News
- Sutro Biopharma (NASDAQ:STRO) had its price target raised by analysts at HC Wainwright from $2.00 to $10.00. They now have a "neutral" rating on the stock.MarketBeat
- Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswire
- Sutro Biopharma (NASDAQ:STRO) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.MarketBeat
- Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Sutro Biopharma Announces 1-for-10 Reverse Stock Split [Yahoo! Finance]Yahoo! Finance
STRO
Earnings
- 5/8/25 - Miss
STRO
Sec Filings
- 12/17/25 - Form 8-K
- 12/16/25 - Form 4
- 12/3/25 - Form 8-K
- STRO's page on the SEC website